GLP1R and type 2 diabetes mellitus: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been broadly used to treat T2DM via elevating endogenous GLP-1 level and inhibiting gastric emptying (Pratley and Salsali, 2007).